). Individual reprints of this article and a bound booklet of the entire Symposium on Oncology Practice: Hematological Malignancies will be available for purchase from our Web site www.mayoclinicproceedings.com.
A n estimated 55,000 to 60,000 new cases of nonHodgkin lymphoma (NHL) are diagnosed in the United States annually. 1 Data from the National Cancer Institute have shown that the incidence of NHL increased by 3% annually in the United States in the past 3 decades but seems to have stabilized in the 1990s, with some variation in the rates according to age, ethnicity, and sex. [2] [3] [4] Non-Hodgkin lymphoma is known to be associated with chronic inflammatory diseases such as Sjögren syndrome, celiac disease, and rheumatoid arthritis. Chronic infection also is associated with lymphoma pathogenesis ACVBP = doxorubicin (Adriamycin), cyclophosphamide, vindesine, bleomycin, and prednisone; CHOP = cyclophosphamide, hydroxydaunomycin (doxorubicin), vincristine (Oncovin), and prednisone; CNS = central nervous system; CVP = cyclophosphamide, vincristine, and prednisone; FDG-PET = positron emission tomography with fluorodeoxyglucose F 18; GI = gastrointestinal; HIV = human immunodeficiency virus; IPI = International Prognostic Index; LDH = lactate dehydrogenase; MALT = mucosa-associated lymphoid tissue; NHL = non-Hodgkin lymphoma; PET = positron emission tomography; R-CHOP = CHOP chemotherapy in combination with rituximab as shown by the association between mucosa-associated lymphoid tissue (MALT) lymphomas and Helicobacter pylori infection. 5 Human T-lymphotropic virus 1 is associated with adult T-cell leukemia/lymphoma; Epstein-Barr virus is associated with Burkitt lymphoma; and primary effusion lymphomas have been associated with human herpesvirus 8. Also, an association has been shown between Chlamydia psittaci and ocular adenexal lymphomas. 6 Furthermore, there is also evidence of an association between hepatitis C infections and splenic or large cell lymphomas. 7 Immune suppression also has been associated with an increased risk of NHL. In patients who undergo solid organ transplantation, 8 the risk of lymphoma has been associated specifically with the duration of immunosuppression and with the drugs and doses used. Furthermore, human immunodeficiency virus (HIV) infections have been associated with a substantially elevated risk of NHL compared with the risk in the general population. 9 
DIAGNOSIS
Patients with indolent lymphomas, such as follicular, marginal zone, and lymphoplasmacytic lymphoma, commonly present with slowly progressive and usually painless peripheral lymphadenopathy. Patients sometimes report a history of the involved lymph nodes getting larger and then smaller before a diagnosis is made. Spontaneous regression of some of these lymph nodes can occur, which may delay the diagnostic biopsy while patients receive therapy for a presumed infectious condition. Primary extranodal involvement or systemic symptoms are less common at presentation but are seen more commonly as the disease advances. Systemic B-symptoms, such as fever, night sweats, and weight loss, may develop and may be associated with more advanced or aggressive disease. Precursor T-cell neoplasms Precursor T-cell lymphoblastic leukemia/lymphoma 1.7 Blastic NK cell lymphoma Mature T-cell and NK-cell neoplasms T-cell prolymphocytic leukemia T-cell large granular lymphocytic leukemia Aggressive NK-cell leukemia Adult T-cell leukemia/lymphoma <1 Extranodal T/NK-cell lymphoma, nasal type Enteropathy-type T-cell lymphoma Hepatosplenic T-cell lymphoma <1 Subcutaneous panniculitis-like T-cell lymphoma Mycosis fungoides and Sézary syndrome <1 Primary cutaneous anaplastic large cell lymphoma Peripheral T-cell lymphoma, unspecified Angioimmunoblastic T-cell lymphoma Anaplastic large cell lymphoma 2.4 T-cell proliferation of uncertain malignant potential Lymphomatoid papulosis *MALT = mucosa-associated lymphoid tissue; NK = natural killer.
sometimes is associated with cytopenias. Splenomegaly is seen in approximately 30% to 40% of patients, but the spleen is rarely the only site of disease involvement at presentation.
The clinical presentation of aggressive lymphomas, such as diffuse large B-cell lymphoma, is more variable. Most patients present with lymphadenopathy; however, many present with extranodal involvement. The most common extranodal sites are the gastrointestinal (GI) tract, skin, bone marrow, sinuses, thyroid, or central nervous system (CNS). B-symptoms are more common in patients with aggressive NHL and occur in approximately one third of patients. Patients with lymphoblastic lymphoma often present with an anterior mediastinal mass that is sometimes associated with superior vena cava syndrome. Patients in the United States with Burkitt lymphoma may present with a large abdominal mass. Patients with African Burkitt lymphoma may present with a mass at the angle of the jaw or in the neck.
No effective methods are available for screening patients for lymphoma, and identifying populations at high risk of lymphoma is challenging. Currently, patients are identified only after they develop lymphadenopathy or other symptoms associated with their disease. Despite progress in imaging techniques for lymphoma, histology remains compulsory to establishing the diagnosis because successful therapy for most patients with NHLs requires an accurate pathologic diagnosis. Excisional diagnostic biopsy is recommended, and a definitive diagnosis can be made only after biopsy specimens of the pathologically involved lymph node are reviewed by an expert hematopathologist. For patients with intra-abdominal and retroperitoneal lymphadenopathy as the only sites of disease, laparoscopy has a role in establishing the diagnosis. Laparoscopy often allows for a more substantial biopsy specimen of intra-abdominal and retroperitoneal disease than is commonly obtained with a needle biopsy, but with less morbidity than a laparotomy.
Routine morphologic examination of excisional biopsy specimens provides the cornerstone for establishing a definitive diagnosis. Fine-needle aspiration biopsies or large bore-needle biopsies can be used but often lead to challenges in making a definitive diagnosis. Because of the limitations of pure morphology, subclassification of NHL by needle biopsy often requires ancillary studies. The list of ancillary studies used to complement the routine approaches is increasing in both number and complexity, and limited tissue availability can hamper attempts to confirm the diagnosis. Because of these challenges and a high likelihood of an incorrect diagnosis, the use of fine-needle aspiration techniques is strongly discouraged. 10 Patient disease usually is classified with use of the World Health Organization classification for lymphoid malignancies (Table 1) , 11 which categorizes on the basis of cytology, immunophenotype, and genetic and clinical features (Tables 2 and 3 ). Chromosomal translocations and molecular rearrangements are used commonly to confirm the diagnosis and may play an important role in the pathogenesis of many lymphomas. The most commonly associated chromosomal abnormality in NHL is the trans- Ig-κ T-cell lymphoma t(2;5)(p23;q35) Anaplastic large cell (Ki-1 positive) npm, alk *alk = anaplastic lymphoma kinase gene; API-2 = apoptosis inhibitor 2; IgH = immunoglobulin heavy chain; Ig-κ = immunoglobulin κ light chain; Ig-λ = immunoglobulin λ light chain; MALT = mucosa-associated lymphoid tissue; MALT-1 = MALT lymphoma gene 1; npm = nucleophosmin gene. *MZL/MALT = marginal zone/mucosa-associated lymphoid tissue; sIg = surface immunoglobulin; SLL = small lymphocytic lymphoma; -= negative; + = positive; dim+ = dimly positive.
location of t(14;18)(q32;q21), which is found in 85% of follicular lymphomas and 28% of diffuse large B-cell lymphomas. [12] [13] [14] This translocation results in the juxtaposition of the bcl-2 gene on chromosome 18 to the heavy chain region of the immunoglobulin locus on chromosome 14 and leads to cellular resistance to apoptosis. The t(11;14)(q13;q32) translocation, which is associated with mantle cell lymphoma, results in the overexpression of bcl-1, leading to increased cell proliferation. Molecular rearrangements involving bcl-6 or c-myc are seen frequently in diffuse large B-cell lymphoma and Burkitt lymphoma, respectively.
The initial evaluation of a patient with recently diagnosed lymphoma should include a medical history and physical examination, a complete blood cell count, electrolyte panel, renal and liver profiles, as well as a bone marrow aspirate and biopsy. Lactate dehydrogenase (LDH) levels should be determined as a measure of tumor cell proliferation and for prognostic purposes. β 2 -Microglobulin also has been shown to predict response to treatment and time to treatment failure, and testing is performed routinely at some centers. 15 Also, diagnostic imaging should be performed including computed tomography of the neck, chest, abdomen, and pelvis, as well as positron emission tomography (PET) for both staging and prognostic purposes.
Positron emission tomography with fluorodeoxyglucose F 18 (FDG-PET) shows functional metabolic status and gives quantitative information for patients with lymphoma. Positron emission tomography provides whole-body images that allow a comprehensive assessment of disease extent during the staging and follow-up. 16 When used in conjunction with computed tomography, PET provides complementary initial staging information. A pretreatment FDG-PET study is essential for subsequent accurate assessment of residual masses and early monitoring of response to treatment. Particularly in diffuse large B-cell and Hodgkin lymphoma, FDG-PET has shown high accuracy in the early prediction of response to chemotherapy and in the evaluation of residual masses after therapy. Persistent abnormalities on PET during and after chemotherapy appear to have a high sensitivity for predicting subsequent relapse. Normal PET at the end of therapy correlates with a highly favorable prognosis. Persistent abnormalities on PET at the end of therapy warrant close follow-up or additional diagnostic procedures (such as a repeated biopsy) because increased FDG uptake may constitute residual disease. However, despite abnormalities on PET Involvement of lymph node regions on both sides of the diaphragm accompanied by both localized involvement of an extralymphatic organ or site and the spleen IV Disseminated (multifocal) involvement of 1 or more extralymphatic organs with or without associated lymph node involvement IV E Isolated extralymphatic organ involvement with distant (nonregional) nodal involvement after treatment, some patients may remain in prolonged remission.
An evaluation of cerebrospinal fluid should be considered in patients with diffuse large cell NHL with bone marrow involvement, a high LDH, or multiple extranodal sites of disease 17, 18 as well as in patients presenting with epidural masses, testicular involvement, paranasal sinus, or nasopharyngeal involvement. A cerebrospinal fluid evaluation also should be performed in patients with high-grade lymphomas, such as lymphoblastic lymphoma or Burkitt lymphoma, and in patients with HIV-related lymphomas, primary CNS lymphomas, and posttransplantation lymphoproliferative disorders. A GI evaluation should be considered in patients with a known GI primary lymphoma or in patients with mantle cell lymphoma because of a high incidence of occult GI involvement. Because of a high incidence of contralateral involvement, ultrasonography of the opposite testis in patients with testicular lymphoma is recommended.
STAGING AND PROGNOSTIC FACTORS
The stage of lymphoma is categorized with use of the Ann Arbor Staging Classification (Table 4) . 19 This system was proposed originally for Hodgkin disease and is based on the distribution and number of involved sites, as well as the presence or absence of extranodal involvement and constitutional symptoms. Such symptoms include weight loss greater than 10% of body weight over the preceding 6 months, fever higher than 38C unrelated to any infections, and drenching night sweats.
The outcome of patients with lymphoma is highly variable, and the histology and morphology of the lymphoma are the major determinants of treatment outcome and prognosis. Some patients with indolent lymphoma may remain well for many years with minimal or no therapy, whereas the survival of patients with aggressive lymphoma may be measured only in weeks unless aggressive treatment is initiated promptly. Even within histological subtypes there is a wide range of disease outcomes, and factors that reliably predict the patient's response to therapy and eventual outcome are used as a standard for discussing prognosis, selecting therapy, and comparing results of clinical trials.
The International Prognostic Index (IPI) was developed initially to categorize aggressive NHL on the basis of easily obtained clinical features that were independent predictors of survival (Table 5) . 20 This model includes patient age (>60 vs 60 years), Ann Arbor stage (III or IV vs I or II), LDH level (>1 vs 1 × normal level), the number of extranodal sites (2 vs <2), and performance status (Eastern Cooperative Oncology Group Performance Status 2-3 vs 0-1). Because younger and older patients may have different outcomes and younger patients may be considered for more aggressive therapies, an age-adjusted model for patients aged 60 years or younger also has been developed. The IPI also appears useful in predicting the outcome of patients with indolent lymphoma, 21 mantle cell lymphoma, 22 refractory large B-cell lymphoma in those undergoing stem cell transplantation, 23 and T-cell lymphomas. 24 The IPI was designed for aggressive lymphoma and may not clearly identify patients with indolent lymphoma who are at high risk; thus, a new prognostic factor model has been devised for follicular lymphoma. 25 The Follicular Lymphoma International Prognostic Index uses the patient's age (>60 vs 60 years), Ann Arbor stage (III or IV vs I or II), hemoglobin level (<12 g/dL vs 12 g/dL), number of nodal areas (>4 vs 4), and serum LDH level ( Table 6 ). Nodal areas are defined as cervical, axillary, inguinocrural, para-aortic and/or iliac, celiac and/or mesenteric, and other ancillary nodal sites including the epitrochlear and popliteal areas. Within each IPI risk group, the Follicular Lymphoma International Prognostic Index can discriminate patients with significantly different death risks and may better define patient groups that may benefit from more aggressive therapy. To determine the biological reason for different outcomes within a lymphoma subgroup, recent research has focused on patterns of gene expression that correlate with different pathologic entities and clinical outcomes. Gene expression profiling using DNA microarrays has been used to develop a molecular prognostic model. 26 Three molecularly distinct forms of diffuse large B-cell lymphoma have been categorized. One group has a germinal center B-cell signature, a second group has a signature of activated B cells, and a third group (termed type 3) has a signature suggesting substantial host immune cell involvement in the area of lymphoma. Patients with the germinal center Bcell-like diffuse large B-cell lymphoma have experienced significantly improved survival compared with the other subgroups. By using a similar microarray technology, 27 2 categories of patients have been identified with substantially different outcomes after 5-year survival following treatment: this model effectively delineated patients in the IPI intermediate-risk categories who were likely to be cured or to die of their disease. These molecular findings also appear relevant in indolent NHL. Recently, a study evaluating genes related to cells in the tumor microenvironment in follicular lymphoma showed that the intratumoral immune signature has significant prognostic importance.
28

TREATMENT
Non-Hodgkin lymphoma generally responds to most modalities of treatment including radiation therapy, singleagent or combination chemotherapy, immunotherapy, or radioimmunconjugate therapy. Treatment commonly involves a combination of these modalities. Opinions are reasonably uniform regarding treatment in most clinical situations; however, some variation exists in the choice of agents used for treating lymphoma as well as the duration and doses of treatment.
Surgery is useful only in selected situations, most commonly to establish a diagnosis by obtaining an excisional biopsy specimen. Because lymphoma is a systemic illness, resection of the sites of disease is used only in selected situations. Surgery may be particularly useful in GI lymphomas when the disease is localized or when there is a risk of perforation. Furthermore, orchiectomy is commonly the initial treatment for patients with testicular lymphoma. Radiation therapy also plays a limited role in the treatment of NHL but is particularly useful in localized disease or for palliation of symptoms. However, chemotherapy is the most important therapeutic modality, particularly for lymphomas with an aggressive phenotype such as diffuse large B-cell lymphoma. In indolent lymphomas, such as follicular lymphoma, the use of monoclonal therapy as well as radioimmunoconjugate therapy has become standard and is used commonly early in the disease course.
FOLLICULAR LYMPHOMA Follicular lymphomas are characterized by a comparatively long survival (median survival, 8-12 years). Many patients are relatively asymptomatic at diagnosis, and most patients present with advanced-stage disease. Because of the biology of this disease, most patients are not cured. However, the goal of treatment should be complete remission. It is important to note that patients with follicular grade 3 lymphoma have a more aggressive disease course and generally are treated similarly to patients with large cell lymphoma.
The standard treatment for patients with follicular lymphoma is controversial and ranges from a watch-and-wait approach, to targeted treatment with monoclonal antibody therapy or radioimmunoconjugate therapy, to combination chemotherapy. A substantial proportion of patients are asymptomatic at presentation, and the toxicity associated with treatment needs to be weighed against potential benefit. However, most patients will require treatment within a few years because of symptoms related to disease progression, potential organ compromise, cosmetic concerns due to unsightly nodes, or severe anxiety.
Patients with stage IA to IIA follicular NHL commonly are treated with radiation therapy, particularly if the disease appears to be confined to clinically involved lymph nodes that could be encompassed adequately by an irradiation field with acceptable toxicity. [29] [30] [31] Radiation typically is given to the entire involved lymph node region or to the involved region plus 1 uninvolved region on each side of the involved nodes. The recommended dose is approximately 30 Gy for nonbulky disease showing prompt response or approximately 36 Gy for bulky or slowly regres- [32] [33] [34] -a fact that must be considered in making a treatment decision. The choice of frontline therapy for advanced follicular lymphoma is controversial, and currently, multiple strategies are offered, ranging from observation until symptomatic to combination chemoimmunotherapy (Table 7) . Chemotherapy options for these patients include single-agent chemotherapy such as chlorambucil or cyclophosphamide with or without the addition of prednisone 35, 36 or combinations such as cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. 37 Other options include more aggressive chemotherapy such as cyclophosphamide, hydroxydaunomycin (doxorubicin), vincristine (Oncovin), and prednisone (CHOP) 38 or the use of purine analogues either alone or in combination, particularly fludarabine or cladribine. [39] [40] [41] Rituximab, used either alone or combined with these agents, has resulted in high response rates and long progression-free survival.
Immunotherapy has become a standard component of therapy for patients with follicular advanced lymphoma. Rituximab is a chimeric human murine monoclonal antibody that binds CD20 on both malignant and benign B cells. Response rates of between 30% and 80% have been seen in patients with indolent lymphoma 42, 43 ; however, response rates primarily depend on patient selection. Rituximab also has been combined with chemotherapy such as CHOP 44 and CVP, 45 resulting in high complete response rates and long durations of response. Also, recent data suggest that continued, scheduled use of single-agent rituximab after initial remission induction results in encouraging response rates and increased time to subsequent treatment. 46 The use of cytokines such as interleukin 2, 47 interferon α, 48 and interleukin 12 49 combined with rituximab to potentiate the patient's immune response have been shown to be safe; however, response rates appear similar to those seen with rituximab alone. Iodine I 131 tositumomab 50 and yttrium Y 90 ibritumomab tiuxetan 51 also have been developed for the treatment of follicular B-cell lymphomas. Both contain murine anti-CD20 antibodies with β-emitting radioisotopes; however, iodine I 131 tositumomab also emits gamma irradiation. Both agents result in a high overall response rate and complete response rates greater than those seen with rituximab. However, currently in the United States, most patients are treated with combined chemotherapy and rituximab.
MALT LYMPHOMA
MALT lymphomas are indolent in nature and commonly present with localized disease, but gastric MALT lymphomas require a different therapeutic approach if associated with H pylori. The stomach is the most frequent site of involvement, but MALT lymphomas also may involve the lung, thyroid gland, salivary gland, breast, or eye orbit. MALT lymphomas that present in organs other than the stomach are treated with curative intent with local radiation therapy, provided the disease is limited to the involved primary organ or site. In gastric MALT lymphoma, the proliferation of the lymphoma cells has been shown to be associated with the presence of H pylori. Combination therapy with omeprazole, metronidazole, and amoxicillin to eradicate the infectious agent has resulted in regression in most early cases and is used commonly as frontline treatment. Of note, tumors invading beyond the submucosa or lesions with a translocation t(11;18) are less likely to respond to H pylori eradication. Radiation therapy for patients not infected by, or failing to respond to, H pylori eradication consists of approximately 30 Gy directed to the stomach and perigastric lymph nodes. 52, 53 For patients in whom this therapy fails, rituximab or chemotherapy, or in some cases surgery, has been used. For patients with MALT lymphoma at other sites presenting with localized disease, surgery or radiation therapy produces durable remissions. Patients with disseminated MALT lymphoma are treated similarly to patients with follicular lymphoma.
DIFFUSE LARGE B-CELL LYMPHOMA
During the past 30 years, treatment of diffuse large B-cell NHL has evolved from the use of radiation therapy alone to NON-HODGKIN LYMPHOMA: DIAGNOSIS AND TREATMENT garded as the standard of care. More recently, the Groupe d'Etude des Lymphomes de l'Adulte (GELA) group randomized patients older than age 60 years with advanced large B-cell lymphoma to 8 cycles of CHOP chemotherapy or 8 cycles of CHOP chemotherapy combined with rituximab (R-CHOP). 59 With a median follow-up of 5 years (Figure 1 ), the group found significant improvement in event-free and overall survival when rituximab was added to CHOP chemotherapy. 60 Toxicity was not found to be significantly greater in the R-CHOP arm. The Eastern Cooperative Oncology Group has confirmed these findings in elderly patients, 61 and R-CHOP has been found to be superior to CHOP in younger patients 62 and in a population-based study. 63 Therefore, R-CHOP has become standard therapy in the United States for all patients with large cell NHL. However, not all groups regard R-CHOP as standard therapy; CHOP with etoposide (CHOEP) and ACVBP combined with rituximab are regarded as standard regimens in Europe. Despite being a standard frontline treatment, R-CHOP is curative in only about 50% of patients, and new treatment approaches are clearly necessary, particularly for patients with poor prognostic features.
PERIPHERAL T-CELL LYMPHOMA
Peripheral T-cell lymphomas are uncommon but often present with nodal or extranodal disease that is clinically similar to B-cell lymphomas. In contrast to B-cell lymphomas, numerous unusual clinical syndromes may be associated with peripheral T-cell lymphoma. The hemophagocytic syndrome, characterized by fever, hepatosplenomegaly, liver function abnormalities, thrombocytopenia, and erythrophagocytosis, can be seen in patients with peripheral T-cell lymphomas. Patients may present with pulmonary infiltrates and/or CNS involvement and associated systemic symptoms. Patients also may present with destructive, necrotic facial or sinus tumors associated with an angiocentric proliferation of T cells or with a systemic illness, liver dysfunction, and unusual organ infiltration by mature T cells.
The management of peripheral T-cell lymphomas has not been well-defined, but therapy should be based on the stage of disease and the specific immunopathologic disease entity. However, the complete response rate in patients with peripheral T-cell lymphoma may be lower than in patients with B-cell lymphomas treated with the same chemotherapy combination. Because of a paucity of comparative trials for this disease, there is little evidence that any particular combination chemotherapy is superior to the others. Therefore, it is reasonable to consider use of an anthracycline-containing regimen such as CHOP as frontline therapy for these diseases. the use of combination chemotherapy with the addition of rituximab. The most commonly used chemotherapy regimen for diffuse large B-cell NHL is CHOP combined with rituximab. Radiation therapy usually is added for patients with limited-stage disease.
For patients with localized disease, a combination of anthracycline-based chemotherapy with involved field radiation therapy is currently the standard of care. In a Southwest Oncology Group study, patients with stage I/IE or nonbulky stage II/IIE disease were randomized to receive either 8 cycles of CHOP or 3 cycles of CHOP combined with involved field radiation therapy. 54 Patients in the chemoradiation arm did significantly better regarding disease-free survival and overall survival. The 5-year diseasefree survival and overall survival showed an advantage in the chemoradiation arm. However, the combination modality therapy advantage was lost at 7 and 9 years, as reported in a recent update. 55 A second study by the Eastern Cooperative Oncology Group randomized patients with stage I or II aggressive lymphomas to either CHOP chemotherapy for 8 cycles or CHOP chemotherapy for 8 cycles plus involved field radiation therapy. 56 This study also showed a benefit in disease-free survival for patients treated with combination therapy; however, an overall survival benefit was not seen. A recent study comparing the doxorubicin (Adriamycin), cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) chemotherapy regimen to 3 cycles of CHOP plus radioimmunotherapy showed an advantage to the chemotherapy-only arm. 57 Of note, these studies did not include the use of rituximab; however, until further studies are done to define the optimal therapy for limited-stage nonbulky large cell lymphoma, many consider an abbreviated course of CHOP with rituximab plus involved field radiation therapy to be the initial treatment of choice. For patients with bulky disease, a minimum of 6 cycles of CHOP chemotherapy combined with rituximab is typical. Radiation doses of approximately 30 to 35 Gy delivered to the involved sites is standard.
Over the years, many different chemotherapy regimens have been used as first-line treatment for patients with advanced-stage NHL. To determine the best frontline therapy, a randomized phase III study was performed to compare CHOP chemotherapy with m-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone), ProMACE-CytaBOM (prednisone, doxorubicin, cyclophosphamide, and etoposide followed by cytarabine, bleomycin, vincristine, methotrexate), and MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin). 58 No significant differences were observed between the 4 arms in terms of response rates, disease-free survival, or overall survival, and CHOP chemotherapy has been re-Certain disease entities deserve special consideration. Patients with nasal T/NK-cell lymphomas commonly present with localized disease and therefore should be treated with combination chemotherapy followed by involved field radiation therapy. Other disease entities such as hepatosplenic T-cell lymphomas and intestinal T-cell lymphomas often have an extremely poor prognosis, and patients with these entities should be considered for autologous stem cell transplantation if they respond well to initial therapy. Intestinal T-cell lymphoma also may present as a GI emergency (obstruction, perforation, hemorrhage) and may require surgical intervention.
MANTLE CELL LYMPHOMA
For patients with mantle cell lymphoma, the outcome is poor, with a median survival of approximately 3 years and extremely few long-term survivors. Clinical outcome does not appear to be influenced by conventional chemotherapy. Treatment with doxorubicin, vincristine, and dexamethasone alternating with cytarabine and methotrexate (hyper-CVAD-AM) has shown significantly increased response rates 64 ; however, the disease-free survival curve fails to plateau, with persistent relapses in this patient population. Many patients are considered for autologous or allogeneic stem cell transplantation during their first complete or partial remission, particularly those with advanced-stage disease or poor risk features. 65 Other approaches as initial therapy (some still investigational) for this disease include the use of R-CHOP chemotherapy, radioimmunoconjugate therapy, idiotype vaccines, or nonmyeloablative allogeneic stem cell transplantation.
LYMPHOBLASTIC LYMPHOMA
Patients with lymphoblastic lymphoma currently are treated with acute lymphocytic leukemia-like regimens such as multiple drug combinations and incorporation of intrathecal chemotherapy due to the propensity for CNS relapse. 66 Maintenance therapy for 2 to 3 years is also necessary, and this strategy has resulted in complete response rates of approximately 80% and long-term survival rates of approximately 45%. For patients with adverse prognostic features, consolidation therapy within autologous or allogeneic stem cell transplantation after completion of induction therapy is a reasonable approach.
BURKITT LYMPHOMA
Patients with Burkitt lymphoma or one of its variants are treated commonly with a brief-duration, high-intensity regimen incorporating CNS prophylaxis. 67, 68 Selected patients with high-risk features are then candidates for autologous or allogeneic bone marrow transplantation during FIGURE 1. Event-free survival (top), progression-free survival (middle), and overall survival (bottom) with a median follow-up of 5 years in elderly patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydaunomycin (doxorubicin), vincristine (Oncovin), and prednisone (CHOP) and rituximab plus CHOP (R-CHOP). Log-rank test P values are <.001, <.001, and .007, respectively. From Feugier et al, 60 with permission from the American Society of Clinical Oncology. their first complete or partial remission. Today, most adult patients with Burkitt lymphoma are cured.
STEM CELL TRANSPLANTATION
In patients with relapsed follicular NHL, high-dose chemotherapy followed by autologous stem cell transplantation has been shown to be superior to standard therapy in a randomized study regarding progression-free survival and overall survival. 69 Salvage chemotherapy for patients with large cell lymphoma that relapses also commonly includes high-dose chemotherapy followed by peripheral blood stem cell transplantation. The Parma study, which randomized patients with relapsed large cell lymphoma to either high-dose chemotherapy with autologous stem cell transplantation or to conventional chemotherapy with DHAP (dexamethasone, cisplatin, cytarabine) plus involved field radiation therapy to sites of bulky disease, showed a benefit for patients treated in the stem cell transplantation arm. 70 Transplantation currently does not have a well-defined role in the primary therapy for aggressive lymphomas but is considered for high-risk patients who achieve a complete response to initial conventional chemotherapy. However, the late effects of transplantation need to be considered because the risk of myelodysplastic syndrome and acute myeloid leukemia is significant. 71, 72 Although lower relapse rates are reported after allogeneic stem cell transplantation, this treatment usually is reserved for relapse after autologous transplantation, primarily because of a high incidence of treatment-related mortality. However, allogeneic transplantation has an important antilymphoma effect in patients with follicular lymphoma and should be considered in younger patients with this disease. The use of nonmyeloablative or reduced-intensity allogeneic transplants has significantly decreased the early treatment-related mortality; however, the long-term immunological effects related to graft-vs-host disease remain similar between nonmyeloablative allogeneic transplants and full allogeneic transplants.
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THE FUTURE
Currently, multiple new and novel agents are being developed for treatment of NHL. Molecular profiling of tumors has allowed the prognosis to be determined more accurately and has potentially identified new targets for treatment. New monoclonal antibodies against a wide range of T-cell and B-cell surface markers are in clinical development. Other strategies, including vaccine strategies, antisense oligonucleotides, and other novel small molecules, are being developed for treatment of this disease.
Future studies will need to be done to determine their role in NHL. The Symposium on Oncology Practice: Hematological Malignancies will continue in the September issue. 
Introduction
The disease we now call diffuse large B-cell lymphoma has gone by many names in the past. These have included reticulum cell sarcoma, 1 diffuse histiocytic lymphoma, 2 and, more recently, diffuse mixed lymphoma, diffuse large cell lymphoma, or immunoblastic lymphoma-terms from the Working Formulation. 3 Early studies of therapy for patients with diffuse large B-cell lymphoma contained some patients with aggressive T-cell lymphoma, as these were lumped together in the Working Formulation and some older classifications. The correct diagnosis today is diffuse large B-cell lymphoma, as used in the World Health Organization (WHO) classification (Table 1) . 4 However, we know that this is still a heterogenous group that includes lymphomas with a wide variety of morphologic appearances (Table 2) , protein-expression patterns, and gene-expression patterns. For example, patients with diffuse large B-cell lymphoma can be divided into at least 3 clinically relevant groups using gene-expression profiling. [5] [6] [7] These include the germinal-center type, the activated B-cell type, and mediastinal large B-cell lymphoma (Table 3 ). A few patients will not easily be classified into these categories. 8 Mediastinal large B-cell lymphoma represents less than 10% of all large B-cell lymphomas, occurs primarily in young women, and always presents with a mediastinal mass. The gene-expression profile is similar to that seen in classical Hodgkin disease. 7, 9 The other 2 types of diffuse large B-cell lymphoma, and those not easily classified, have a median age at presentation in the 60s, a male predominance, and can present at essentially any site in the body. 8 They will be the major focus of this paper.
Lymphomas are the fifth most common systemic cancer, with the most common subtype being diffuse large B-cell lymphoma followed by follicular lymphoma and Hodgkin lymphoma. Diffuse large B-cell lymphoma represents approximately 30% of all lymphomas and is the most common subtype throughout the world. This is in contrast to many other types of lymphoma, which have striking geographic variation in frequency of occurrence. 10 Diffuse large B-cell lymphoma can be seen after histologic transformation of most other types of B-cell lymphoma. This is particularly frequent in patients with follicular lymphoma and is recognized clinically in up to 50% of patients. 11, 12 Although much less frequent, this transformation occurring in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma has the eponym Richter transformation. 13, 14 In general, patients with diffuse large B-cell lymphoma seen after histologic transformation have a poorer response to therapy and prognosis than those with a de novo appearance, particularly if the patient were treated for the preceding lymphoma. This manuscript will focus on the treatment of patients with primary diffuse large B-cell lymphoma.
Diagnosis
The first step in treating any cancer is an accurate histologic diagnosis. For non-Hodgkin lymphomas in general, and diffuse large B-cell lymphoma in particular, the initial diagnosis should be based on an adequate sample of tissue preferably obtained with an excisional biopsy of an abnormal lymph node or a generous incisional biopsy of an involved organ. In some cases, cuttingneedle biopsies can provide adequate tissue for diagnosis; however, the diagnosis of lymphoma based on fine-needle aspirates should be discouraged. One of the most frustrating situations in the care of a patient with lymphoma arises when the diagnosis was based on inadequate material, the patient does not respond to therapy as expected, and to obtain another biopsy has become difficult or impossible.
The diagnosis of lymphoma and its subtype is best made by a hematopathologist with experience in diagnosing lymphomas. Expert hematopathologists using the WHO classification can make highly reproducible diagnoses for most subtypes of lymphoma. 15 However, this depends upon adequate tissue and the availability of immunohistochemistry. 15 On occasion, cytogenetics or fluorescent in situ hybridization (FISH) may help clarify a difficult diagnosis.
At the present time, gene-expression profiling is not part of routine clinical practice. This may be partly because of the technical difficulties in performing the arrays. The assignment of germinal-center-type versus non-germinal-center-type diffuse large B-cell lymphoma seems to be able to be reproduced by studying the expression of 3 proteins using immunohistochemistry. 16 Although the germinal-center B-cell type and the activated B-cell type of diffuse large B-cell lymphoma do not have the same prognosis with anthracycline-containing chemotherapy regimens, 8 they are still treated in a similar way in the absence of studies showing superiority of specific regimens for each subtype. The poorer prognosis of patients with primary brain diffuse large B-cell lymphoma and the better outcome in pediatric patients might be partly explained by the predominance of activated B-cell type in the former 17, 18 and germinal-center B-cell type in the latter. 19, 20 The one time that gene-expression profiling may be important in current clinical practice is in the distinction between diffuse large B-cell lymphoma and Burkitt lymphoma. A recent study showed that gene-expression profiling might be able to make this distinction more accurately than other studies. 21 This is important because patients with Burkitt lymphoma should be treated with different For personal at STATE UNIV OF N Y AT BUFFAL on August 14, 2011. bloodjournal.hematologylibrary.org From regimens from those used for diffuse large B-cell lymphoma, and their survival is dramatically better when they receive appropriate regimens.
In my practice I am extremely reluctant to treat a patient for diffuse large B-cell lymphoma in the absence of an adequate biopsy reviewed by experienced hematopathologists. I prefer rebiopsy to guessing about the correct diagnosis.
Staging/restaging
As would be true for any type of cancer, after the diagnosis of diffuse large B-cell lymphoma a patient must be evaluated to determine sites of involvement by the lymphoma and the presence or absence of key prognostic factors to complete a staging evaluation. 22 As currently used in practice today, the process of staging accomplishes several important tasks. These include allowing the choice of the most appropriate therapy, providing the most accurate possible prognosis for the patient and their family, and making clinical research and quality assessment possible by allowing patients to be stratified into prognostic groups. In potentially curable diseases such as diffuse large B-cell lymphoma, this initial evaluation will be the basis for "restaging" that will be done after some or all of the patient's treatment. This restaging will document the presence or absence of a complete response to treatment. Obviously, cure of the disease requires a complete response to therapy, but not all complete responders will be cured, as our current tests cannot always find minimal residual lymphoma. Conversely, some patients with apparent incomplete responses due to residual masses on computed tomograms might be cured if the residual masses contain no active lymphoma. This problem is at least partially addressed by the use of functional imaging such as positron emission tomography (PET) scans.
The initial evaluation of a patient with diffuse large B-cell lymphoma should include a careful history and physical examination and laboratory studies including hematologic parameters, screening chemistry studies, and, specifically, a serum lactate dehydrogenase level. Imaging studies should include at least computed tomograms of the chest, abdomen, and pelvis and a PET scan if available. An adequate bone marrow biopsy should be performed. Other laboratory studies, images, and biopsies might be appropriate for specific patients. For example, I perform lumbar puncture to rule out meningeal involvement in patients presenting with testicular, epidural, or sinus involvement.
PET scanning is an increasingly important tool in the care of patients with diffuse large B-cell lymphoma. However, the best use of this technology is still in flux and basic issues such as what represents a negative PET scan after treatment does not have general agreement. Whether scans need to be done before treatment Data adapted from Rosenwald et al, 8 Iqbal et al, 61 and Dybkaer et al. 84 Adapted with permission from Jaffe et al. 4 30 ARMITAGE
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in a disease with a high likelihood of positivity such as diffuse large B-cell lymphoma has been debated. 23 The appropriate timing for follow-up scans has also been a point for controversy. A recent consensus report on the use of PET scanning in lymphomas is a step toward trying to resolve these areas of uncertainty. 24 Patients with diffuse large B-cell lymphoma are stratified into prognostic groups based on the International Prognostic Index (IPI). 25 This system uses anatomic stage, performance status, the number of extranodal sites, serum lactate dehydrogenase level, and age to predict treatment outcome ( Table 4 ). The IPI remains our most useful prognostic tool and should be applied to all patients with diffuse large B-cell lymphoma (Table  5) . However, the improvement in treatment response associated with the addition of the antibody rituximab to treatment regimens seems to have altered the survival of prognostic groups using the IPI (Table 6) . 26 Restaging is a process of repeating all previously abnormal tests to see if the patient has achieved a remission. Although this is often done at the completion of a planned course of therapy, I perform restaging after 4 cycles of treatment for diffuse large B-cell lymphoma, with the intention of treating patients 2 cycles past documented complete remission. 27 Thus, if the patient is in remission at 4 cycles, they receive a total of 6. If they do not achieve remission until after 6 cycles, they would receive a total of 8 cycles. If they have not achieved a remission by 6 cycles, then I would switch to alternate therapies.
Therapy
The discussion of management of patients with diffuse large B-cell lymphoma can be conveniently divided into 3 groups: those presenting with localized disease, those presenting with disseminated disease, and those patients whose lymphoma recurs after an initial remission. In each group, patients who are elderly might not be managed in exactly the same way as young patients. Also, patients who have the disease involving specific organs might require special treatment approaches.
Localized disease
Patients with stage I diffuse large B-cell lymphoma (ie, involvement of only one lymph-node region or isolated organ involvement) fit into this category of localized disease; however, selected patients with stage II (ie, 2 adjacent lymph-node regions involved or organ involvement with involvement of regional lymph nodes) who could have their disease encompassed in one radiotherapy port might be approached in a similar manner. These patients were once treated with radiotherapy alone and a few were cured. 28 The addition of adjuvant chemotherapy following the radiation improved treatment outcome, 29 but an abbreviated course of chemotherapy followed by radiation became the most popular treatment. 30 A study done by the Southwest Oncology Group in the United States showed superiority of an abbreviated course of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) followed by radiation over a complete course of CHOP alone. 31 This became and has remained the standard treatment in the United States. A more recent Eastern Cooperative Oncology Group study suggested benefit of adjuvant radiation after 8 cycles of CHOP. 32 However, selected patients in whom radiation might be unusually problematic (eg, young women in whom the treatment field would involve the breast or patients of any age in whom salivary gland treatment might lead to a dry mouth and loss of teeth) are often treated with a complete course of chemotherapy alone. Adapted with permission from Sehn et al. 26 HOW
l'Adulte (GELA) study in elderly patients compared 4 cycles of CHOP alone with 4 cycles of CHOP followed by radiotherapy. 33 There was no advantage to the radiation and, in fact, a possible disadvantage in patients older than 70 years of age. In younger patients, the same group compared an intensive chemotherapy regimen (ACVBP [doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone]) to 3 cycles of CHOP followed by involved field radiotherapy. 34 There was a significant advantage to the ACVBP arm. The Mabthera International (MINT) trial included some patients with minimal disease and compared a CHOP-like chemotherapy regimen to the same regimen with the addition of rituximab in young good-prognosis patients. 35 For the most favorable patients (ie, those without bulky disease), the results with a complete course of chemotherapy plus rituximab alone and no radiation led to a survival in excess of 90%. The Southwest Oncology Group in the United States reported a pilot study of an abbreviated course of CHOP plus the antibody rituximab followed by radiation and also showed progression-free and overall survival in excess of 90%. 36 My personal approach to patients with localized diffuse large B-cell lymphoma involves the use of CHOP plus rituximab for 4 cycles. If the patient is in remission at that point, either involved field radiotherapy or 2 more cycles of the chemotherapy regimen would be administered based on the patient's preferences and the site of the disease. I would generally not recommend radiation to young women in whom the breast would have to be irradiated and would offer drugs alone to patients in whom radiation to the salivary glands might lead to loss of their teeth. For the patient with very bulky (ie, Ͼ 10-cm mass) but localized lymphoma, I would favor CHOP plus rituximab for 6 cycles followed by involved field irradiation.
Patients with localized disease involving certain organs need modifications of the general plan. Patients with testicular lymphoma have a predilection for the disease to spread to the opposite testis and to the central nervous system. 37 Central nervous system involvement can be meningeal or parenchymal. In addition, patients with testicular involvement, who are usually elderly men, have a higher than anticipated risk of late relapse. They would usually be treated with a complete course of chemotherapy such as CHOP plus rituximab accompanied by intrathecal treatment with methotrexate and/or cytarabine. After treatment, these patients should have scrotal irradiation. [37] [38] [39] [40] Primary brain lymphoma is an increasing problem. 41 While often accompanied by HIV infection, an increasing number of patients without HIV are developing the disease. Current treatment regimens are built around high-dose methotrexate. 41 The use of whole-brain radiotherapy as part of the initial treatment is controversial and frequently associated with the development of dementia, particularly in elderly patients. Patients with epidural or sinus presentations and those with circulating tumor cells seem especially likely to develop meningeal metastasis. These patients should be treated with intrathecal methotrexate and/or cytarabine along with their initial chemotherapy regimen.
Disseminated disease
The potential for cure using chemotherapy alone in patients with disseminated diffuse aggressive lymphoma was first reported in the early 1970s by Levitt et al 42 and DeVita et al. 43 In both studies, some patients with documented complete remissions achieved long-term disease-free survival. Shortly after these reports, the CHOP regimen became popular in the United States and became the standard treatment regimen for patients with diffuse aggressive lymphoma. 44 However, in the subsequent decade, the development of new treatment regimens including M-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone), 45 MACOP-B (methotrexate with leucovorin rescue doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin), 46 and ProMACE/CytaBOM (cyclophosphamide, doxorubicin, etoposide cytozar, bleomycin, vincristine, methotrexate prednisone) 47 were reported to achieve results that seemed much better than had been observed with CHOP. These so-called third-generation regimens appeared to represent an important advance in therapy until an intergroup trial carried out in the United States demonstrated no superiority over CHOP. 48 This surprising result was almost certainly related to treating a better group of patients (ie, probably younger, lower stage, with a lower IPI score) in the studies of the new very intensive regimens and assuming that the results would apply to all patients with the disease. This example illustrates the importance of the randomized trial in documenting moderate improvements in therapy in this and any other disease.
After the disappointing results with the third-generation chemotherapy regimens in the United States, there was a lull in developing new regimens and CHOP was the standard therapy. However, research continued, particularly in countries other than the United States, and a number of new treatment approaches have been developed. Currently, the search for the optimal chemotherapy regimen for treating diffuse large B-cell lymphoma continues.
The GELA developed the ACVBP regimen (ie, that involves very intensive chemotherapy for 4 courses followed by an intensive consolidation), which was shown to be superior to CHOP in subgroups of patients. 49 In Germany, national trials found that the addition of etoposide to CHOP improved results in young patients, 50 whereas CHOP administered at 14-rather than 21-day intervals seemed to improve the results in elderly patients. 51 An infusional chemotherapy regimen developed at the United States National Cancer Institute referred to as EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) had very encouraging results. 52 This regimen plus rituximab is currently in a randomized trial in the United States.
However, the study that changed practice throughout the world was performed by the GELA and compared CHOP versus the same regimen plus the antibody rituximab in elderly patients. 53, 54 A highly significant advantage in response rate, failure-free survival, and overall survival was seen with the addition of the antibody. In the United States, a trial comparing CHOP with or without rituximab administered in a different schedule and with or without maintenance rituximab generally confirmed the GELA results, with a significant advantage for receiving rituximab either during induction or maintenance but no advantage to getting both. 55 An international study called the MINT trial compared chemotherapy with CHOP or a "CHOP-like" regimen with or without rituximab in younger good-prognosis patients (ie, both the GELA and the America Intergroup trials were done in patients older than 60 years of age). 35 The MINT trial demonstrated a significant advantage in response, failure-free survival, and overall survival with the addition of the antibody. The German High-Grade Lymphoma Study Group studied the utility of 6 versus 8 cycles of CHOP at 14-day intervals with or without rituximab in elderly patients with diffuse large B-cell lymphoma. Again, this demonstrated the importance of rituximab but also hinted that 8 cycles of treatment might be deleterious in very elderly patients. 56 Finally, investigators from the Cancer Institute in British Columbia had the opportunity to do a population-based study of the impact of adding rituximab to CHOP. 57 Because cancer drugs are paid for by the government in British Columbia and the addition of rituximab to CHOP was approved at a particular point in time, they used that point in time as the variable to see if approval of the drug improved treatment outcome. This was despite the fact that a few patients received the drug before the date of approval and not all patients received the drug after the date of approval. However, with only approval of the drug and its general availability as a variable, survival for diffuse large B-cell lymphoma in British Columbia increased by about 20% (Figure 1) . 57 The addition of rituximab to CHOP or other chemotherapy regimens has been a major improvement in our ability to treat patients with diffuse large B-cell lymphoma. An important question has been whether or not all patients need the rituximab. Studies from France and the American National Cancer Institute suggested that the improvement with rituximab was largely seen in patients with tumors overexpressing the Bcl-2 protein, 58, 59 although not all groups found the same results. 60 This might relate to the Bcl-2 protein expression having prognostic significance in the activated B-cell type but not the germinal-center B-cell type of diffuse large B-cell lymphoma. 61 A recent report from the French group using the method of competing risks suggested that benefit was seen in both Bcl-2-positive and Bcl-2-negative lymphomas but that the benefit was more striking in those patients whose tumors were Bcl-2 positive. 62 Autologous hematopoietic stem cell transplantation has been shown to be an effective therapy for patients with diffuse large B-cell lymphoma who relapsed from complete remission and whose lymphoma still responded to standard-dose salvage chemotherapy. 63 In a randomized trial comparing DHAP (dexamethasone, cytarabine, and cisplatin) plus radiotherapy to autologous hematopoietic stem cell transplantation, patients who underwent transplantation had a superior disease-free and overall survival. 64 Benefit from transplantation was seen in patients with an IPI score of 1 or higher. 65 Because of these encouraging data, a large number of studies have tested the value of incorporating autologous hematopoietic stem cell transplantation into the primary therapy of patients with diffuse large B-cell lymphoma. [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] These studies were not all comparable with some studies testing transplantation early in the course of therapy with an abbreviated standard treatment regimen: some have used novel treatment regimens, some have studied complete and partial responders, some but not all have incorporated only high-risk patients, and some have tested transplantation as an adjuvant treatment following complete remission. Although the interpretation of these data remains a point for controversy, the conclusion that I draw is that transplantation is only likely to benefit high-risk patients who achieve a complete remission after a complete course of a standard chemotherapy regimen. The results from a randomized French trial that restricted analysis to patients with an age-adjusted IPI score of 2 or 3 are presented in Figure  2A . 70 The progression-free survival curve for 53 high-risk patients who received a transplant in first complete remission following a complete course of anthracycline-based chemotherapy treated at the University of Nebraska Medical Center is presented in Figure  2B . One important issue to consider is that the definition of high risk may change as new treatment approaches are developed. For example, a recent report from the University of British Columbia in Vancouver suggested that the results by IPI score have "shifted" with the addition of rituximab (Table 6 ). 26 
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My treatment approach for patients with disseminated diffuse large B-cell lymphoma who are not participating in a clinical trial is to initiate CHOP plus rituximab after starting the patient on allopurinol, as tumor lysis syndrome can be seen in this disease. Patients received concomitant intrathecal methotrexate if the testis, sinus, or epidural area were involved at presentation. After 4 cycles of treatment, I reevaluate the patient with history and physical examination, laboratory studies, and images including PET scan. If the patient has achieved a complete remission, I give 2 more cycles of therapy and discontinue treatment. If the patient presented with a very bulky (ie, Ͼ 10 cm) mass at any site, I would consider adjuvant radiotherapy to that site if it could be administered safely. If the patient were 60 years of age or younger and had a high serum lactate dehydrogenase level, poor performance status, multiple extranodal sites of disease, and Ann Arbor stage III or IV (ie, or at least 2 of these findings), I would discuss adjuvant autologous hematopoietic stem cell transplantation in complete remission as an option. I do not believe there is any evidence to support maintenance therapy in patients with this disease.
Follow-up
After a patient has completed planned therapy and is in complete remission, there is still a significant chance for recurrence. Most patients who are going to relapse will do so in the first 2 or 3 years, but we have seen patients relapse more than 13 years after completing therapy. Follow-up is aimed at identifying relapse but also at managing the complications that might develop related to the treatment and at helping patients deal with the diagnosis and their concerns about possible relapse. I see patients at 2-month intervals for the first year, 3-month intervals for the second year, 4-month intervals for the third year, twice a year for the fourth and fifth years, and then annually indefinitely. While this follow-up pattern is arbitrary, I believe that seeing the patient more often early after treatment is useful to the patient.
Follow-up visits include interval history, careful physical examination, and laboratory studies including a complete blood count, chemistry screen, and serum lactate dehydrogenase level. Once a complete remission is documented, I would do no more images in the absence of some abnormality hinting at relapse or at the patient's request. I know it is standard care in much of the United States to do routine images in complete remission, but this approach cannot be supported with data. There is no convincing evidence that routine images in remission accomplish their goal of improving survival by finding early relapse, although this could be tested in a prospective trial. While there is at best minimal evidence that routine images in remission could improve survival, 77 it is certain that they are expensive. Whether these studies make a patient less anxious because a negative test is reassuring, or make them more anxious by reminding them that they should be afraid of relapsing, is a point that could be argued. However, given the specificity and sensitivity of the tests and the chances of relapse at any particular point in time, it can be shown that abnormal findings on routine images are much more likely (ie, Ͼ 80% of the time) to represent false positives and lead to inappropriate further evaluation or, even worse, instituting inappropriate therapy. 78 A major mistake to avoid in following patients with diffuse large B-cell lymphoma in complete remission is to initiate therapy for apparent relapse without a biopsy. While most patients with new lymphadenopathy will have recurrent lymphoma, it is certainly not true for all. Table 7 lists the diagnoses that my colleagues and I have found on biopsy in patients with "obvious" recurrent lymphoma. Patients who have never been diagnosed with lymphoma would not be treated without a biopsy and neither should patients who are being followed in documented complete remission.
Salvage therapy
Unfortunately, some patients with diffuse large B-cell lymphoma will not respond to their initial treatment, not achieve an initial complete remission, or relapse from remission. True, primarily refractory patients occasionally benefit from alternate chemotherapy regimens but, in general, have very poor outlook. Partial responders will sometimes benefit further from an alternate chemotherapy regimen and might undergo autologous hematopoietic stem cell transplantation. Some of these patients will be long-term, disease-free survivors. Patients who relapse from complete remission and are younger than 60 to 65 years of age are usually offered hematopoietic stem cell transplantation, and a significant subset of these patients can be cured. 63, 64 If patients respond to an alternate chemotherapy regimen and achieve a complete remission, approximately 50% of these patients will be long-term disease-free survivors, with a smaller proportion surviving free of disease after a partial response. Salvage chemotherapy regimens today often include a platinum-containing agent, but it is unclear that one regimen is distinctly superior to others. Patients who relapse after an autologous hematopoietic stem cell transplantation can occasionally be rescued with allogeneic hematopoietic stem cell transplantation. [79] [80] [81] Some patients relapsing after autologous transplantation seem unusually responsive to rituximab and can have prolonged survival. I have seen a small number of patients have prolonged survival using rituximab and [alpha] interferon. 82 For patients with localized relapse, involved field radiotherapy can be used but durable responses are the exception rather than the rule.
The future
The future for treating patients with diffuse large B-cell lymphoma is likely to be exciting. Advances in functional imaging will change staging and restaging and may make other tests obsolete. Further understanding of the genetic subtypes and the associated patterns of protein expression is likely to lead to individualized therapy based on knowing that lymphomas expressing certain proteins (ie, associated with activation of specific metabolic pathways) are particularly likely to respond to specific agents. Among the first Table 7 . Diagnoses from biopsies in "obviously" relapsed patients For personal at STATE UNIV OF N Y AT BUFFAL on August 14, 2011. bloodjournal.hematologylibrary.org From hints at this approach are the apparent disproportionate benefit of patients with the activated B-cell type of diffuse large B-cell lymphoma from treatment with rituximab 83 and the rare patient with a durable response to a salvage regimen after failing CHOP plus rituximab. We already cure a significant proportion of patients with diffuse large B-cell lymphoma. Almost certainly this proportion will continue to rise. 
Authorship
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Introduction
Almost 60 000 new cases of non-Hodgkin lymphoma (NHL) were diagnosed in the United States in 2006. 1 NHL is extremely heterogeneous in its molecular pathophysiology, histology, and clinical course, and there are major differences in the incidence of subtypes in different geographical locations and among different racial and ethnic populations. The World Health Organization (WHO) lymphoma classification 2 is based on cell of origin and pathophysiology of the lymphoma and does not include the terminology "indolent lymphoma," which is defined as one which "tends to grow and spread slowly and has few symptoms" (http://www.nih.gov/). The indolent lymphomas encompass the low-grade and some categories of intermediate-grade NHL in the working formulation.
For indolent lymphomas the goal of therapy has been to maintain the best quality of life and treat only when patients develop symptoms. Any alteration to this approach requires demonstration of improved survival with early institution of therapy, or identification of criteria that define patients sufficiently at "high risk" to merit early therapy. There are many available therapies and no consensus on an optimal first-line or relapse treatment. The following discussion presents my approach for the management of indolent lymphoma based on 25 years of clinical practice in oncology, research, and review of the work of distinguished colleagues. Literature is cited where available to support treatment practice and recommendations.
Indolent lymphoma
The frequency of the indolent lymphomas by the WHO classification is shown in Table 1 . 3 By far the most common is follicular lymphoma (FL), the second most common subtype of lymphoma worldwide, accounting for approximately 20% of malignant lymphomas in adults, but 40% of all lymphomas diagnosed in the United States and in Western Europe. 4 FL is derived from germinal center B cells and maintains the gene expression profile of this stage of differentiation. 5 Morphologically, the disease is composed of a mixture of centrocytes and centroblasts and is graded from I to III, depending on the proportion of large cells per high-power field. Grades I and II are indolent disease. The rare subtype grade IIIb is more aggressive, and I manage this entity like diffuse large B-cell lymphoma. FL cells express CD19, CD20, CD22, and surface immunoglobulin, and 60% express CD10. A hallmark of the disease is t(14;18), contributing to overexpression of the antiapoptotic protein BCL2. Median age at presentation is 60 years, and men and women are equally affected. Patients usually present with asymptomatic lymphadenopathy, most cases are advanced stage, and 50% have bone marrow involvement at presentation. Lymphadenopathy may wax and wane, and spontaneous remissions can occur, albeit rarely. 6 Disease transformation to a more aggressive histologic type is a common terminal event. 7 Until recently there was little evidence that the natural history of FL had changed over the past 30 years from the median survival of 10 years from diagnosis, 8 but this may be changing with the introduction of monoclonal antibodies in combination with chemotherapy, with more recent data suggesting that with improvements in treatment the median survival is now 12 to 14 years. 9, 10 The clinical course is extremely variable, with some patients having an extremely aggressive course and death within 1 year, whereas others may live for more than 20 years and never require therapy. It is vital that samples from patients are studied in the laboratory to determine the biologic characteristics associated with progression, with response to therapy, to identify surrogate markers of response, and to identify targets for new drug development, which can then be tested in subsequent clinical trials. My approach is shown in Figure 1 .
How I diagnose indolent lymphoma
Suggested guidelines for the diagnosis of indolent lymphomas have been outlined by the National Comprehensive Cancer Network (guidelines available at http://www.nccn.org/) and by the European Society for Medical Oncology. 11 In all cases possible, I confirm diagnosis by excisional biopsy of an accessible lymph node (LN) with review by an expert hematopathologist with expertise in lymphoma diagnosis. Fine-needle aspiration is not appropriate for diagnosis in these conditions. I obtain informed consent for use of excess tissue from LN biopsies at the time of presentation and at each subsequent relapse of disease for research purposes to investigate the molecular biology of these diseases. Initial staging workup includes a computed tomography scan of the chest, abdomen, and pelvis and a bone marrow aspirate and biopsy. I pay particular attention to sites of bulk disease. I use the Follicular Lymphoma International Prognostic Index (FLIPI) score to assess risk of progression. 12 How I follow patients I follow patients remaining on expectant course every 3 months for history, physical examination, and blood counts, including LDH. Special attention is paid to any change in symptoms that might be suggestive of transformation. I have a very low threshold to recommend repeat biopsy to examine for histologic evidence of transformation. I do not routinely perform repeat scanning unless this is indicated by symptoms or signs.
Depending on the treatment approach used, I usually restage after 2 to 3 cycles of therapy to ensure responsiveness and fully restage after completion of therapy. Staging of response in indolent lymphomas is by the revised response criteria. 13 Although we now seek curative approaches in indolent lymphomas, the failure to achieve complete remission (CR) or complete eradication of disease does not have the same implication in indolent lymphomas as in aggressive lymphomas and a partial remission (PR) may be a sufficient response to therapy to alleviate symptoms. The impact of newer technologies such as positron emission tomography (PET), which are included in the revised guidelines for aggressive lymphomas, 13 have been much less studied in the indolent lymphomas. There is considerable heterogeneity in uptake of fluorine-18 fluoro-deoxyglucose based on histology, but PET demonstrates 94% sensitivity and 100% specificity for staging in FL. 14 I do not use PET scans routinely in patients with indolent lymphomas, but I have found them useful to direct biopsy in cases where transformation is suspected.
When I institute therapy
My current practice is to offer all eligible patients inclusion in clinical trials. This ensures delivery of optimal care and helps inform design of subsequent trials, hopefully, leading to cure. Information on available clinical trials can be found at http:// www.clinicaltrials.gov/. I continue to use expectant management for asymptomatic patients with low-bulk disease until clear indications for initiation of treatment are seen, except for those patients enrolled in clinical trial assessing the impact of early therapy. This approach is based on the demonstration of no survival advantage for institution of immediate compared with deferred treatment until time of progression. 15 In addition, 3 randomized trials, performed in the era before rituximab, confirmed no survival benefit for early therapy. [16] [17] [18] In the National Cancer Institute study in 104 patients with newly diagnosed FL, deferred treatment was compared with immediate treatment with cyclophosphamide 650 mg/m 2 intravenously, doxorubicin 25 mg/m 2 intravenously, etoposide 120 mg/m 2 intravenously on day 1, mechlorethamine 6 mg/m 2 intravenously, vincristine 1.4 mg/m 2 intravenously on day 8, prednisone 60 mg/m 2 orally daily on days 1 to 14, procarbazine 100 mg/m 2 orally daily on days 8 to 14, methotrexate 500 mg/m 2 intravenously on day 15 with leucovorin 50 mg/m 2 orally every 6 hours for 4 doses beginning 24 hours after methotrexate with cycles repeated every 28 days (ProMACE-MOPP) followed by total nodal irradiation. An updated analysis of this data is long overdue, but there was no difference in overall survival (OS) between the 2 arms at the time of the last analysis. 16 The Groupe pour l'Etude de Lymphome Folliculaire (GELF) used defined criteria for patients in whom immediate therapy was not felt to be indicated (Table 2) and randomly assigned 193 patients to deferred treatment or to receive prednimustine 200 mg/(m 2 / ⅐ day) for 5 days per month for 18 months or IFN-␣ 5 MU/day for 3 months then 5 MU 3 times per week for 15 months. 17 The median OS time was not reached and was the same in all 3 arms of the study. The British National Lymphoma Investigation (BNLI) 18 compared treatment in 309 patients with asymptomatic advanced-stage, indolent lymphoma in whom 158 patients were randomly assigned to receive immediate therapy with oral chlorambucil 10 mg/day continuously, and 151 patients were randomly assigned to deferred treatment until disease progression (Table 2) . In both arms, local radiotherapy to symptomatic nodes was allowed. There was no difference in OS or cause-specific survival between the 2 groups with 16 years median follow-up. A meta-analysis of more than 2000 patients with early-stage chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) showed no difference in survival between early versus deferred therapy using alkylating agents. 19 A major clinical trial question is whether identification of clinical or molecular risk factors can identify which patients are candidates for early therapy. The FLIPI is a 5-factor prognostic index based on the clinical characteristics, age, stage, number of nodal sites, and hemoglobin and LDH levels, and it defines 3 prognostic risk groups of almost equal numbers of patients. 12 This tool is useful in assessing the likely need for early treatment of patients and potential outcome, as well as in comparing the outcomes of different clinical trials. A survival predictor score has also been developed from gene expression profiling studies. 5 The results from that study suggest that the molecular determinants of biologic heterogeneity are already present in the diagnostic LN biopsies rather than by the later acquisition of secondary genetic changes. A major component of the gene expression prognostic signature is related to immune cells in the tumor microenvironment. [20] [21] [22] Future guidelines for treatment will likely be based on clinical staging systems, genetic profiles and immune response signatures, but these factors do not yet help us to decide who should have immediate therapy.
From available data there is little to suggest that we should change our practice of watch and wait for asymptomatic patients with low-bulk disease, but data demonstrate that this practice is becoming much less common in the United States. 23 The National LymphoCare study is a prospective observational study designed to assess presentation, prognosis, treatment, and clinical outcomes in newly diagnosed FL. The treating physician determines management according to clinical judgment with no prescribed treatment regimen, and data regarding histology, stage, therapy, response, relapse, and death are recorded. Among 1493 patients enrolled at 237 centers, 26% of initially observed patients had switched to active therapy after a median of 2.8 months on observation since diagnosis, and by the first follow-up visit only 19% of patients continued on watch and wait at 6 months (Table 3 ). This observation is in stark contrast to the data from the BLNI study demonstrating that censored for nonlymphoma death 19% of patients and 40% for those older use only.
For personal at STATE UNIV OF N Y AT BUFFAL on August 14, 2011. bloodjournal.hematologylibrary.org From than 70 years randomly assigned to expectant management still did not require therapy at 10 years. 18 I initiate treatment in patients with symptomatic disease, bulky lymphadenopathy or splenomegaly or both, risk of local compressive disease, marrow compromise, or rapid disease progression. Once treatment is indicated, many treatment approaches are available ( Table 4 ). The concept that the approach can be to "do nothing" or discuss an approach with considerable rates of morbidity and mortality such as stem cell transplantation (SCT) is a confusing one for the patient with newly diagnosed disease (as well as for the physician), and considerable consultation time is required to review available treatment approaches.
Optimal first-line treatment is enrollment in randomized clinical trials. In the National LymphoCare study 23 academic sites are more likely than community sites to treat patients on clinical trials (12% versus 4%), but it is lamentable that such a small proportion of these patients are enrolled in clinical trials. For patients who are not eligible for or who refuse entry into clinical trials, my preferred first-line therapy is chemoimmunotherapy, based on data demonstrating higher response rates, longer duration of responses, and perhaps improved survival with this approach. I favor alkylatorover fludarabine-based regimens for FL, based on concerns about the ability to obtain stem cells for later use for autologous SCT in patients treated with fludarabine. 24 I offer more aggressive first-line therapy for patients who progress within 1 year of presentation, because these patients have a worse outcome. 17 Elderly patients or those with poor performance status remain candidates for singleagent chlorambucil. Single-agent monoclonal antibody therapy is appropriate for patients who chose to avoid chemotherapy, and I discuss the results of clinical trials of prolonged or maintenance therapy with rituximab. Although data suggest a survival advantage with the use of interferon ␣ (IFN-␣) in combination with chemotherapy, this is associated with a significant side effect profile, and I rarely use this agent. Although optimal results are seen when radioimmunoconjugates are used earlier in the disease course, I reserve these agents for later in the disease course. I do not consider the use of SCT in first remission in FL unless in a randomized clinical trial. I also enroll all possible patients with CLL/SLL in randomized clinical trials. If patients refuse trial entry, my current treatment of choice is fludarabine, cyclophosphamide, and rituximab (FCR), based on the high response rates and long duration of responses observed in phase 2 studies. 25 Fludarabine or chlorambucil immunotherapy may be indicated when there is impaired performance status. I consider patients with CLL/SLL for allogeneic SCT in first remission if they had particularly poor prognostic features and had not achieved CR with optimal front-line therapy. 26 Data from the National LymphoCare study demonstrate that chemoimmunotherapy is now the treatment of choice of physicians in the United States (Table 3) . 23 No randomized trials demonstrate a benefit for the addition of anthracyclines, but CHOP-R is heavily favored over CVP-R or fludarabine-based regimens. Choice to initiate therapy was associated with FLIPI, stage, and grade, but FLIPI was not associated with decision to use a specific treatment approach. Significant regional and center differences were observed, strongly suggesting that physician preference is the predominant factor that drives initial therapy. For example, initial watch and wait was used in 31% in the Northeast but in 13% in the Southeast, whereas fludarabine-based chemoimmunotherapy was used in 18% of patients in the Southwest and only 3% in the Northeast.
Alkylating agents
The alkylating agents chlorambucil and cyclophophamide with or without prednisone and CVP or CHOP, and other alkylatorbased combination chemotherapy regimens have been the standard of therapy for decades. Single-agent alkylators at different doses and schedules produce overall response (OR) rates of 50% to 75% in FL. 27, 28 Comparable response rates, but higher CR rates with longer progression-free survival (PFS) are seen with CVP compared with chlorambucil but no survival advantage. 29, 30 The addition of anthracyclines has not improved the response rate or duration of the response, 31, 32 but its use may be associated with a lower risk of histologic transformation. 16, 33 This finding has to be confirmed, particularly in the era of chemoimmunotherapy.
Purine analogues
The purine analogues have been studied extensively in various types of indolent lymphoma. Fludarabine monotherapy produces response rates of 65% to 84%, with 37% to 47% CR in patients with previously untreated FL. 34 In a randomized trial of 381 patients with previously untreated indolent lymphoma CR rates were higher with fludarabine than with CVP. 35 Fludarabine combinations result in increased response rates, with 89% CR rate in a Eastern Cooperative Oncology Group (ECOG) trial combining fludarabine and cyclophosphamide (FC), 36 whereas fludarabine and For personal at STATE UNIV OF N Y AT BUFFAL on August 14, 2011. bloodjournal.hematologylibrary.org From mitoxantrone (FM) produced a 91% overall response rate (ORR), 43% CR, and 2-year disease-free survival (DFS) of 63%. 37 A higher CR rare was seen with FM (68%) compared with CHOP (42%) in a randomized trial. 38 The use of alkylator-based regimens or purine analog-based regimens appears to vary geographically, suggesting personal preference for the use of regimens in which the clinician has experience, rather than alterations of practice based on the results of the published studies. In CLL/SLL, fludarabine is associated with a higher response rate and longer duration of response than chlorambucil 39 but no OS advantage. The use of fludarabine in combination with cyclophosphamide is associated with a higher response rate and longer duration of response compared with fludarabine alone in randomized trials. 40 The highest response rates have been with FCR. 25 
Biologic therapy
IFN-␣ is approved by the Food and Drug Administration (FDA) for the treatment of advanced-stage FL in combination with anthracycline-based chemotherapy, based on improved survival in a clinical trials 12, 41, 42 and meta-analysis of phase 3 trial data. 43 IFN-␣ has been widely used in Europe but not in the United States, where it is felt that its toxicity profile outweighs any potential benefit. In the Southwest Oncology Group (SWOG) study, 44 571 patients with stage III and IV indolent lymphoma were treated with ProMACE-MOPP, and 279 responding patients were randomly assigned to 24 months of observation versus treatment with IFN-␣. No statistically significant difference in PFS or OS was observed between observation and IFN-␣ groups at 4 years.
Monoclonal antibody therapy
I consider the monoclonal antibodies to be the most exciting agents to emerge in the treatment of indolent lymphomas, and recent data suggest their use may finally be leading to improvement in patient survival. 9, 10 The most widely used monoclonal antibody is rituximab, a chimeric unconjugated antibody against the CD20 antigen licensed by the FDA 45 and the European Agency for the Evaluation of Medicinal Products 46 for treatment of patients with relapsed or refractory CD20 ϩ low-grade FL; for the first-line treatment of CD20 ϩ FL in combination with CVP chemotherapy, and for the treatment of CD20 ϩ low-grade NHL in patients with stable disease or who achieve a PR or CR following first-line treatment with CVP chemotherapy.
Following phase 1 studies, 47 rituximab at a dose of 375 mg/m 2 weekly for 4 weeks was selected for the pivotal phase 2 trial, and this remains the standard dose. 48 In patients with relapsed indolent lymphoma OR was 48% and 60% in FL. Median PFS for responders was 13 months. Factors associated with lower response rates include chemo-resistant disease, 48 bulky disease, 49 and treatment late in the disease course. 50 OR was 73% in previously untreated patients with low-bulk disease, 51 and some of these patients have needed no further treatment and have no evidence of polymerase chain reaction (PCR)-detectable minimal residual disease (MRD) after 7 years. 52 Extended use with 8 weeks instead of 4 weeks is associated with improvement in OR and duration of response. 53 Comparable or even longer durations of response have been observed with retreatment. 54 A number of trials in front-line therapy and in relapsed or refractory patients have investigated the potential benefits of extended or maintenance rituximab treatment, [55] [56] [57] [58] [59] and all demonstrated prolonged time to progression in patients receiving maintenance rituximab ( Table 5 ). The results from the E1496 randomized trial from ECOG and Cancer and Leukemia Group B comparing CVP alone with CVP followed by rituximab in patients with advanced-stage FL demonstrated that the addition of rituximab maintenance significantly improved OS 55 and led to FDA approval for rituximab therapy in patients responding to CVP chemotherapy. A problem with interpretation of the role of maintenance therapy or in recommending a specific regimen is that there is no standard schedule, and trials have been performed in rituximab naive patients, as well as in patients treated with previous rituximab monotherapy or combination chemoimmunotherapy as shown in Figure 2 .
Chemoimmunotherapy
In a phase 2 study 40 patients with indolent lymphoma were treated with 6 infusions of rituximab (375 mg/m 2 per dose) in combination with 6 doses of CHOP chemotherapy (R-CHOP), 60 OR was 95% with 55% CR, with 45% OR in patients with bulky disease. In a phase 2 study of 40 patients with indolent lymphomas rituximab in combination with fludarabine produced OR of 90% with 80% CR, with similar response rates in treatment nave and previously treated patients. 61 A number of randomized trials show a benefit for the use of rituximab with chemotherapy compared with chemotherapy alone (Table 6 ). 57, [62] [63] [64] [65] Each study showed an improvement in TTF, and more recent follow-up data suggests improved OS in patients use only.
For personal at STATE UNIV OF N Y AT BUFFAL on August 14, 2011. bloodjournal.hematologylibrary.org From treated with chemoimmunotherapy compared with chemotherapy alone. A meta-analysis of these trials demonstrates that OS, OR, and disease control are significantly better in those on chemoimmunotherapy compared with chemotherapy for FL and mantle cell lymphoma. 66 Data from the German Low-grade Study Group (GLSG) suggest that it is the addition of rituximab that has led to the recent improvement in survival of patients with FL. 10 A recent independently assessed analysis of the clinical benefits provided by rituximab in relation to cost concluded that it is highly cost effective. 67 
Conjugated-radiolabeled monoclonal antibody therapy
Complexing a radioisotope to a monoclonal antibody (radioimmunoconjugate) might be expected to improve efficacy over antibody therapy alone. Tositumomab complexes 131 I to the anti-B1 antibody and has been studied extensively in the treatment of heavily pretreated, 68 untreated, 69 and for retreatment of indolent lymphomas. 70 Best responses are seen in patients with previously untreated FL with a 95% OR, 75% CR, and 80% of assessable patients achieving eradication of PCR-detectable MRD for patients treated with a single treatment course with tositumomab. 69 Median PFS was 6.1 years, with 40 patients remaining in remission for 4.3 to 7.7 years, and no cases of myelodysplastic syndrome were observed. A SWOG study investigated chemoimmunotherapy with 6 cycles of CHOP chemotherapy followed 4 to 8 weeks later by tositumomab in 90 patients with previously untreated, advanced-stage FL. 71 The OR was 91%, including 69% CR, and at median follow-up time of 5.1 years the estimated 5-year OS was 87% and PFS was 67%, 23% better than CHOP alone on previous SWOG protocols. Ibritumomab tiuxetan is a 90 Y-labeled anti-CD20 antibody and produced an OR of 74% and 15% CR in 57 patients with FL refractory to rituximab. 72 Toxicity is primarily hematologic, with nadir counts occurring at 7 to 9 weeks and lasting approximately 1 to 4 weeks. The risk of hematologic toxicity increased with dose delivered and with degree of baseline bone marrow lymphoma involvement. 73 An acceptable safety profile was observed in relapsed patients with less than 25% lymphoma marrow involvement, adequate marrow reserve, platelet counts greater than 100 ϫ 10 9 /L, and neutrophil counts greater than 1.5 ϫ 10 9 /L.
High-dose therapy as consolidation of first remission
The role of high-dose therapy and autologous SCT in patients with FL during first remission was explored in phase 2 trials 74, 75 and in 3 phase 3 randomized trials. [76] [77] [78] The GLSG trial recruited 307 previously untreated patients up to 60 years of age, and patients who responded after induction chemotherapy with 2 cycles of CHOP or MCP were randomly assigned to autologous SCT or IFN-␣ maintenance. 76 Among 240 evaluable patients, the 5-year PFS was 64.7% for ASCT and 33.3% in the IFN-␣ arm (P Ͻ .001). Acute toxicity was higher in the ASCT group, but early mortality was below 2.5% in both study arms. Longer follow-up is necessary to determine the effect of ASCT on OS. In the Groupe Ouest Est des Leucemies Aigues et des Maladies du Sang study, 172 patients with newly diagnosed advanced FL were randomly assigned either to cyclophosphamide, doxorubicin, teniposide, prednisone (CHVP) and IFN-␣ or to high-dose therapy followed by purged ASCT. 77 Patients treated with high-dose therapy had a higher response rate than patients who received chemotherapy and IFN-␣ (81% versus 69%, P ϭ .045) and a longer median PFS (not reached versus 45 months), but this did not translate into a better OS because of an excess of secondary malignancies after transplantation. A subgroup of patients with a significantly higher event-free survival rate with autologous SCT could be identified using the FLIPI. The GELF94 study enrolled 401 patients with previously untreated advancedstage FL who were randomly assigned to receive CHVP plus IFN-␣ compared with 4 courses of CHOP followed by high-dose therapy (HDT) with total body irradiation (TBI) and autologous SCT, and OR rates were similar in both groups (79% and 78%, respectively) and 87% of eligible patients underwent ASCT. Intent-to-treat analysis after a median follow-up of 7.5 years showed no difference between the 2 arms for OS (P ϭ .53) or PFS (P ϭ .11). Long-term follow-up demonstrated no statistically significant benefit in favor of first-line ASCT in patients with follicular lymphoma, which they conclude should be reserved for relapsed patients. In view of these results, my opinion is that autologous SCT should be used in first remission only in the setting of clinical trials.
How I treat relapsed indolent lymphoma
The treatment options after relapse remain the same as for first-line therapy (Table 4) , and relapsed patients should ideally be treated in clinical trials. Relapsed asymptomatic disease is not necessarily an indication for treatment, and patients can again be managed expectantly. A number of factors must be taken into account in planning therapy, and it is not possible to define treatment at relapse without considering the goal of use only.
For personal at STATE UNIV OF N Y AT BUFFAL on August 14, 2011. bloodjournal.hematologylibrary.org From therapy (palliative versus potentially curative), performance status, previous therapy, response, and duration of response. Single-agent rituximab is approved for relapsed lymphoma and is widely used in this setting. A multicenter randomized trial in relapsed patients has demonstrated a survival advantage for chemoimmunotherapy with CHOP-R or CHOP followed by R compared with CHOP alone and a further benefit for rituximab maintenance therapy. 57 For younger patients who are suitable candidates for either HDT and autologous SCT or reduced intensity conditioning (RIC) allogeneic transplantation, I discuss the potential role and timing of transplantation. Best results are seen when transplantation is considered early in the course of disease before patients become chemorefractory, and I continue to offer high-dose therapy and autologous SCT for younger patients with chemoresponsive relapsed disease. SCT approaches must be considered in the context of the improving results that are being seen with salvage therapy alone. I no longer consider autologous SCT for CLL/SLL, 79 but I continue to explore RIC allogeneic transplantations, which appear promising in selected patients. 80 
Role of transplantation in relapsed indolent lymphomas
Unlike aggressive lymphomas, the use of high-dose chemotherapy with autologous SCT in the treatment of indolent lymphomas has not yet been fully established. The rationale for considering transplantation is that the disease is incurable using standard approaches, and young patients with indolent lymphomas will die of their disease, and promising results have been observed in a number of phase 2 studies. [81] [82] [83] Detection of MRD has been a useful surrogate marker for tracking long-term PFS in patients examining the autologous stem cells or serial samples after transplantation. 83-87 A major concern relates to the risk of development of secondary myelodysplasia/acute myeloid leukemia. 88 The European Bone Marrow Transplant Registrysponsored CUP (conventional chemotherapy, unpurged, purged autograft) study is the only prospective randomized trial to assess the role of autologous SCT in patients with relapsed FL. 89 The results of the study suggest a PFS and OS advantage of ASCT over conventional chemotherapy, with 4-year OS of 46% for the chemotherapy arm versus 71% for the unpurged and 77% for the purged ASCT arms. The study was closed early because of slow accrual with 140 of the planned 250 patients accrued and only 89 randomly assigned to treatment. In CLL/SLL, the use of HDT and autologous SCT was not associated with improved outcome in patients who received a transplant in first remission compared with those who received a transplant later in their disease course. 79 
Allogeneic BMT
There is increasing use of allogeneic SCT in the management of indolent lymphomas. In a report of the International Bone Marrow Transplant Registry (IBMTR), results after SCT are described for 904 patients with FL. 90 Allogeneic SCT has increased transplantrelated mortality (TRM) but lower risk of relapse, and long-term PFS has been observed after allogeneic SCT even in patients with refractory FL. 91 Outcomes are improving, and TRM decreased with RIC regimens. RIC-incorporating alemtuzumab therapy was associated with a low incidence of graft-versus-host disease, TRM was decreased in patients with indolent compared with higher grade histology, and PFS at 3 years was 65% for patients with indolent lymphoma. 92 The effectiveness of donor lymphocyte infusion to treat relapse after allogeneic SCT provides strong evidence for a graft-versus-lymphoma effect that can be exploited in indolent lymphomas. 79, 92 How I treat patients with limited-stage disease It appears paradoxical that I continue to follow an expectant treatment approach for patients with advanced-stage disease, yet patients with localized (stage I or II) disease for immediate radiation therapy (XRT). This decision is based on the curative potential of this approach in patients with localized disease. [93] [94] [95] [96] No significant survival differences have been observed using involved field versus extended field versus total lymphoid irradiation. 94 Long-term follow-up studies from Stanford of 177 patients with localized FL treated with XRT demonstrated a median survival of 13.8 years, with 20-year survival of 35%. 97 A retrospective study in Stanford in 43 patients with localized disease in whom a watch-and-wait approach was initially followed suggested similar outcome, and more than half of these patients remained untreated for 6 years. 98 The outcome was not worsened by delayed treatment compared with previously observed results. The role of additional chemotherapy or rituximab therapy to XRT in limited-stage disease is being addressed in ongoing clinical trials.
Special circumstances
Mucosa-associated lymphoid tissue (MALT) lymphomas deserve very brief special mention because they behave differently than most other indolent lymphomas and require such different treatment approaches. Bacterial infection with the Gram-negative rod, Helicobacter pylori, is associated with 92% of gastric MALT lymphomas, 99 suggesting that gastric MALT lymphoma is "driven" by H pylori. Combination antibiotics and histamine blocker for eradication of H pylori produces 70% CR in patients with localized gastric MALT lymphomas, independent of local or disseminated disease, with median PFS of 5.6 years with 80% OS at 10 years. 100 The importance of this findings is the suggestion that outcome can be improved with eradication of a factor which drives proliferation of the malignant cells, although putative factors driving other indolent lymphomas have yet to be identified.
Conclusions
Despite any data demonstrating any benefit for early therapy, patients are being treated earlier in their disease course. There is no clear-cut treatment pathway for patients with indolent lymphomas, and, although we have a good evidence base to decide on a particular treatment, there is little or no data regarding the optimal sequencing of treatment approaches in these diseases. In the absence of such data, treatment choices remain empiric and should always involve discussion regarding patient choice and goal of therapy. This is likely to become even more complicated because many novel agents are currently being investigated in preclinical and clinical studies, particularly, novel monoclonal antibodies and agents that alter the antiapoptotic pathways. The impact of these new agents on practice will depend on the results of the ongoing clinical trials, which should always be the treatment of choice in these diseases until we have a clear-cut established treatment approach which leads to cure for the majority of patients. 
